Financial Personal
RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024
The company’s roster of clinical evidence continues to grow, with data highlights on expediting, broadening, and challenging current guidelines in stroke care SAN MATEO, Calif. — RapidAI, the global leader in developing Artificial Intelligence
SAN MATEO, Calif. -- RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM). Other select data from research studies unveiled last week at the American Heart Association’s International Stroke Conference (ISC) underscore and reinforce the pivotal role of the RapidAI platform in advancing stroke care. Read More
Related
Share this page
Guest Posts by Easy Branches